B
Bradley Alexander McGregor
Researcher at Harvard University
Publications - 152
Citations - 3227
Bradley Alexander McGregor is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 18, co-authored 99 publications receiving 1569 citations. Previous affiliations of Bradley Alexander McGregor include Grant Medical Center & San Antonio Military Medical Center.
Papers
More filters
Journal ArticleDOI
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
Jonathan E. Rosenberg,Jonathan E. Rosenberg,Peter H. O'Donnell,Arjun Vasant Balar,Bradley Alexander McGregor,Elisabeth I. Heath,Evan Y. Yu,Evan Y. Yu,Matthew D. Galsky,Noah M. Hahn,Elaina M. Gartner,Juan Pinelli,Shang Ying Liang,Amal Melhem-Bertrandt,Daniel P. Petrylak +14 more
TL;DR: Enfortumab vedotin demonstrated a clinically meaningful response rate with a manageable and tolerable safety profile in patients with locally advanced or metastatic urothelial carcinoma who were previously treated with platinum chemotherapy and anti–PD-1/L1 therapy.
Journal ArticleDOI
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Timothy D Gilligan,Daniel W. Lin,Rahul Aggarwal,David D. Chism,Nicholas G. Cost,Ithaar Derweesh,Hamid Emamekhoo,Darren R. Feldman,Daniel M. Geynisman,Steven L. Hancock,Chad A. LaGrange,Ellis G. Levine,Thomas A. Longo,William T. Lowrance,Bradley Alexander McGregor,Paul Monk,Joel Picus,Phillip M. Pierorazio,Soroush Rais-Bahrami,Philip J. Saylor,Kanishka Sircar,David Smith,Katherine S. Tzou,Daniel A. Vaena,David J. Vaughn,Kosj Yamoah,Jonathan Yamzon,Alyse Johnson-Chilla,Jennifer Keller,Lenora A. Pluchino +29 more
TL;DR: Recommendations for the management of adult patients with nonseminomatous GCTs, the most common solid tumor in men between the ages of 20 and 34 years, are focused on.
Journal ArticleDOI
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
Aly-Khan A. Lalani,Wanling Xie,Dylan J. Martini,Dylan J. Martini,John A. Steinharter,Craig Norton,Katherine M. Krajewski,Audrey Duquette,Dominick Bossé,Joaquim Bellmunt,Eliezer M. Van Allen,Eliezer M. Van Allen,Bradley Alexander McGregor,Chad J. Creighton,Lauren C. Harshman,Toni K. Choueiri +15 more
TL;DR: Early decline and NLR at 6 weeks are associated with significantly improved outcomes in mRCC patients treated with ICB, and the prognostic value of the readily-available NLR warrants larger, prospective validation.
Journal ArticleDOI
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
Kevin Bi,Kevin Bi,Meng Xiao He,Meng Xiao He,Ziad Bakouny,Abhay Kanodia,Abhay Kanodia,Sara Napolitano,Sara Napolitano,Jingyi Wu,Jingyi Wu,Grace Grimaldi,Grace Grimaldi,David A. Braun,David A. Braun,Michael S. Cuoco,Angie Mayorga,Laura DelloStritto,Gabrielle Bouchard,John A. Steinharter,Alok K. Tewari,Natalie I. Vokes,Natalie I. Vokes,Erin Shannon,Maxine Sun,Jihye Park,Jihye Park,Steven L. Chang,Bradley Alexander McGregor,Rizwan Haq,Rizwan Haq,Thomas Denize,Thomas Denize,Sabina Signoretti,Sabina Signoretti,Jennifer L. Guerriero,Sébastien Vigneau,Sébastien Vigneau,Orit Rozenblatt-Rosen,Asaf Rotem,Asaf Rotem,Aviv Regev,Aviv Regev,Toni K. Choueiri,Eliezer M. Van Allen,Eliezer M. Van Allen +45 more
TL;DR: In this article, single-cell transcriptomes of cancer and immune cells from metastatic renal cell carcinoma (RCC) patients before or after immune checkpoint blockade (ICB) exposure are characterized.
Journal ArticleDOI
Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Aly-Khan A. Lalani,Bradley Alexander McGregor,Laurence Albiges,Toni K. Choueiri,Robert J. Motzer,Thomas Powles,Christopher G. Wood,Axel Bex +7 more
TL;DR: The treatment landscape for mccRCC has evolved since the introduction of VEGF inhibitors and combination therapies involving checkpoint inhibitors could be the next standard of care.